← Back

Wire · opportunities

Florence Healthcare Celebrates FDA Approval of RASONQUE a Breakthrough Treatment for ...

Published

17 November 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at clinicalleader.com →

◆ Verified

Fusion42 · 17 November 2026 · Fusion42 review

The FDA approved RASONQUE (daraxonrasib), the first broad RAS-targeted therapy for metastatic pancreatic cancer, showing significant survival benefits over standard chemotherapy in a pivotal Phase 3 trial supported by Florence Healthcare's clinical trial technology across over 200 research sites.

This Wire brief sits within Fusion42's coverage of Biotech, and 48 sources have reported it between 26 Aug 2026 and 17 Nov 2026.

◆ ◆ The Wire takeaway

Your drug targeting pancreatic cancer gains a clear path to the US market and clinical validation. Florence Healthcare’s trial tech is now proven in pivotal studies, opening doors to partnership and operational scale in oncology trials.

◆ Coverage

48 sources · first reported 26 Aug 2026 · latest 17 Nov 2026

◆ Related on Wire

◆ Topics

Biotechfda-approvalpancreatic-canceroncologyclinical-trialsdrug-development